NEPHROGENEX INC COM (NRXGQ1)

Sector:
HEALTH CARE
Industry:
HEALTH CARE
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
John P. Hamill
Employees:
1,700
P.O. BOX 400, JAMISON, PA 18929
6095538887

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

NephroGenex, Inc. is a pharmaceutical company, which focuses on the development of therapeutics to treat kidney disease, an area of significant unmet medical need. It is developing Pyridorin, a small molecule drug that is acting inhibitor of the pathogenic oxidative chemistries which are elevated in diabetic patients. The company was founded by Billy G. Hudson, J. Wesley Fox Ahmann and Tryggvason Karl on May 25, 2004 and is headquartered in Raleigh, NC.

Data derived from most recent annual or quarterly report
Market Cap 1.813 Million Shares Outstanding12.95 Million Avg 30-day Volume 647.672 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.29
Price to Revenue0.0 Debt to Equity0.5835 EBITDA-22.274 Million
Price to Book Value1.8591 Operating Margin0.0 Enterprise Value5.469 Million
Current Ratio2.973 EPS Growth-0.065 Quick Ratio2.843
1 Yr BETA 0.6859 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth-43.9727 Altman Z-Score-6.2686 Free Cash Flow to Firm -14.131 Million
View SEC Filings from NRXGQ1 instead.

View recent insider trading info

Funds Holding NRXGQ1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NRXGQ1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2017-05-24:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-05-19:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-05-11:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-04-21:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-04-20:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-03-24:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-03-15:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-03-01:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2017-02-17:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-02-16:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    STEINER EUGEN

    • Director
    76,045 2015-12-09 0

    LEGAULT PIERRE CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    659,430 2015-11-10 0

    HAMILL JOHN CHIEF FINANCIAL OFFICER

    • Officer
    136,381 2015-11-10 0

    PATEL JAIKRISHNA CHIEF MEDICAL OFFICER

    • Officer
    97,306 2015-11-10 0

    FOX J. WESLEY PRES. & CHIEF SCI. OFFICER

    • Officer
    No longer subject to file 2015-09-01 0

    MARKHAM RICHARD J

    • Director
    • 10% Owner
    0 2015-04-30 0

    TAGLIETTI MARCO

    • Director
    0 2015-04-30 0

    PETERSON BOB VP OF PROD. DEV. & REG. AFF'S.

    • Officer
    No longer subject to file 2015-04-30 0

    SELTZER ROBERT R.

    • Director
    • 10% Owner
    0 2015-04-30 0

    MITCHUM JAMES P.

    • Director
    0 2015-04-30 0

    RHO VENTURES V, L.P.

    RHO VENTURES V AFFILIATES, LLC

    RMV V, L.L.C.

    RHO CAPITAL PARTNERS LLC

    RUCH JOSHUA

    KAIROUZ HABIB

    LESCHLY MARK

    • 10% Owner
    1,052,966 2015-01-02 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments